This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Drug, Biotech Stocks' Q1 Earnings on May 4: REGN, ZTS & More
by Kinjel Shah
Let us look at four big drug and biotech companies, REGN, ZTS, MRNA and NVO, which are gearing up for their earnings release.
Why Earnings Season Could Be Great for Regeneron (REGN)
by Zacks Equity Research
Regeneron (REGN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)?
by Zacks Equity Research
Sector ETF report for PBE
LGND vs. REGN: Which Stock Is the Better Value Option?
by Zacks Equity Research
LGND vs. REGN: Which Stock Is the Better Value Option?
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
by Zacks Equity Research
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
Is a Beat on the Cards for Regeneron's (REGN) Q1 Earnings?
by Zacks Equity Research
Regeneron's (REGN) first-quarter earnings are likely to have gotten a boost from the solid performance of Dupixent.
Regeneron (REGN) Gains But Lags Market: What You Should Know
by Zacks Equity Research
In the latest trading session, Regeneron (REGN) closed at $792.29, marking a +1.84% move from the previous day.
Sanofi (SNY) Q1 Earnings Beat, Sales Miss, Dupixent Strong
by Zacks Equity Research
Sanofi (SNY) beats first-quarter estimates for earnings but misses the same for sales. Higher sales of Dupixent and rare disease drugs drive Specialty Care GBU sales.
Regeneron (REGN) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Regeneron (REGN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Roche (RHHBY) Q1 Revenues Decline on Lower COVID-19 Test Sales
by Zacks Equity Research
Roche's (RHHBY) performance in first-quarter 2023 is pretty ho-hum as COVID-19-test sales continue to decline.
4 Pharma, Biotech Stocks Poised to Beat Q1 Earnings Estimates
by Ekta Bagri
We look at a few pharma/biotech companies, SNY, AMGN, REGN, ACAD, which are poised to beat on earnings in the first quarter.
Regeneron (REGN) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Regeneron (REGN) closed at $800.73, marking a +0.33% move from the previous day.
Looking for Stocks with Positive Earnings Momentum? Check Out These 2 Medical Names
by Zacks Equity Research
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
MAIA Biotechnology (MAIA) Up on Positive Data From NSCLC Study
by Zacks Equity Research
MAIA Biotechnology (MAIA) gains on encouraging data on lead candidate from Part A of its mid-stage study in advanced non-small cell lung cancer.
Will Regeneron (REGN) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
Regeneron (REGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
by Zacks Equity Research
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Kodiak Sciences (KOD) Shares are Up 26% in a Week: Here's Why
by Zacks Equity Research
Shares of Kodiak Sciences (KOD) shot up 26% in the last week after the company announced remaining on track with ongoing studies in its fourth-quarter and full-year 2022 earnings report.
Regeneron (REGN) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Regeneron (REGN) closed at $821.67 in the latest trading session, marking a +1.25% move from the prior day.
Biotech Stock Roundup: VKTX, BMEA, ITCI Soar on Study Data, INCY Faces Setback
by Zacks Equity Research
Pipelines updates from Viking Therapeutics (VKTX) and Intra-Cellular (ITCI) are the key highlights for the biotech sector.
Unity (UNX) Down on Disappointing Results From Wet AMD Study
by Zacks Equity Research
Unity's (UBX) phase II ENVISION study on UBX1325 fails to meet the non-inferiority threshold compared to aflibercept through 24 weeks in the wet AMD study.
The Zacks Analyst Blog Highlights Sanofi, Regeneron, AbbVie, Roche and Eli Lilly
by Zacks Equity Research
Sanofi, Regeneron, AbbVie, Roche and Eli Lilly are included in this Analyst Blog.
Regeneron's (REGN) Dupixent Meets Pivotal COPD Study Goal, Up 7%
by Zacks Equity Research
Regeneron's (REGN) share price rose after it reported data from a late-stage study showing that treatment with Dupixent led to a 30% decline in chronic obstructive pulmonary disease exacerbations.
Pharma Stock Roundup: SNY's COPD Study Meets Goal, ABBV Parkinson's Drug Gets CRL
by Kinjel Shah
Sanofi's (SNY) Dupixent succeeds in a pivotal study for COPD. FDA gives CRL to AbbVie's (ABBV) Parkinson's disease therapy, ABBV-951
ETFs in Focus on Sanofi and Regeneron's COPD Drug Data
by Sanghamitra Saha
Shares of drugmakers Sanofi and Regeneron surged more than 6% on Mar 23 on COPD drug data.
Regeneron (REGN) Soars 6.8%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Regeneron (REGN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.